Explore News By Topic
10/01/2018
MD Anderson Immunologist Jim Allison Awarded Nobel Prize
Original Press Release issued by: MD Anderson News Jim Allison, Ph.D., chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, today was awarded the 2018 Nobel Prize in Physiology or Medicine for launching an effective new way to attack cancer by treating the immune system... Read More
09/13/2018
FinditParts Announces First Ever Matching Donation Campaign in Commercial Vehicle Industry to Raise Funds And Awareness for Prostate Cancer Research
LOS ANGELES (Sept. 12, 2018) -- FinditParts, the number one supplier of heavy duty truck and trailer parts online, today pledged its commitment to the Prostate Cancer Foundation’s (PCF) community fundraising initiative, Many vs Cancer, to match 100 percent of donations made through its website beginning in September which is... Read More
09/04/2018
Immunotherapy could offer hope for some men with aggressive prostate cancers
Original Press Release issued by: The Institute of Cancer Research, London Study finds that a subset of men with prostate cancer have ‘mismatch’ DNA repair defects in their tumours These men have very aggressive disease with worse survival on currently available therapies BUT are more likely to benefit from immunotherapy New... Read More
07/19/2018
Genomic Landscape of Metastatic Prostate Cancer Unveiled in New Study
A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease. As reported in the July 19, 2018 issue of Cell, a team led by investigators at UC... Read More
07/17/2018
NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men
The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun. The $26.5 million study is called RESPOND, or Research on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Tumor Markers, and Social Stress. It will... Read More
07/11/2018
Deadly Form of Advanced Prostate Cancer is Common, Calls for Distinct Treatment
Original article issued by UCSF News. A new study of prostate cancer in 202 men, whose cancers had spread and were resistant to standard treatment, found that a surprisingly large number of these cancers – about 17 percent – belong to a deadlier subtype of metastatic prostate cancer. Previously, it... Read More
07/10/2018
Tumors Grown in the Lab Provide Insights on Rare Prostate Cancer
Original article issued by Weill Cornell Medicine. Growing miniature tumors from patient’s cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer, according a study by Weill Cornell Medicine and NewYork-Presbyterian scientists. Patients with prostate cancer often receive therapies that reduce levels... Read More
06/26/2018
How Your Spit May Help Doctors Diagnose Prostate Cancer
Original article issued by Healthline. It might seem inconceivable that a simple saliva test can tell you your chances of developing cancer. But evidently it can. And the reason is crude but simple: Your genetic makeup can be found in your spit. Scientists are now able to extract DNA from cells... Read More
06/25/2018
Researchers find prostate cancer drug byproduct can fuel cancer cells
Original press release issued by: Cleveland Clinic. A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic. The findings may provide important information for identifying which patients potentially fare better when treated with... Read More
06/14/2018
Non-coding DNA reveals a route by which advanced prostate cancer resists treatment
More than three quarters of metastatic prostate cancers that resist hormone-blocking therapies may harbor several duplicates of both the gene for a treatment resistance factor called the androgen receptor (AR) and of a never-before-seen genetic switch, or enhancer, that boosts the gene's expression. The duplications, as well as epigenetic signs... Read More